Medicenna Therapeutics Corp.

MDNA on TSXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
1.85CAN 0.00/0.00%961.42 / 3.3045.04 M
MDNAF on OTCQXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
1.47US 0.00/0.00%01.29 / 2.2435.82 M

Contact Information

Medicenna Therapeutics Corp.

Headquarters:
1920 Yonge Street , Suite 200
Toronto, Ontario
Canada, M4S 3E2
Tel: (416) 648-5555
Fax: (416) 572-7501
Email: Send a message
Website: Visit website
For more information...
Lead: Laura Welsh

Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs). Its wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna's lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for rGBM at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4- ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

Fahar Merchant, PhD. - President and CEO

Elizabeth Williams, CPA, CA - Chief Financial Officer

Martin Bexon, MD - Head of Clinical Development

Rosemina Merchant, MESc - Chief Development Officer

Patrick Ward, MBA, RPh - Chief Operating Officer

Shafique Fidai, PhD. - Head of Discovery and Corporate Development

Fahar Merchant, PhD. - Chairman

Albert Beraldo, CPA, CA - Director

Dr. William W. Li, M.D. - Director

Rosemina Merchant, MESc - Director, Chief Development Officer

Dr. Chandra Panchal, PhD. - Director

Andrew Strong, JD - Director

Stock Information

Events

Feb 21, 2018 - 12:00 PM EST Corporate Presentation - Philadelphia

Company Overview

Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs). Its wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna's lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for rGBM at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4- ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

Management

Fahar Merchant, PhD. - President and CEO

Elizabeth Williams, CPA, CA - Chief Financial Officer

Martin Bexon, MD - Head of Clinical Development

Rosemina Merchant, MESc - Chief Development Officer

Patrick Ward, MBA, RPh - Chief Operating Officer

Shafique Fidai, PhD. - Head of Discovery and Corporate Development

Board of Directors

Fahar Merchant, PhD. - Chairman

Albert Beraldo, CPA, CA - Director

Dr. William W. Li, M.D. - Director

Rosemina Merchant, MESc - Director, Chief Development Officer

Dr. Chandra Panchal, PhD. - Director

Andrew Strong, JD - Director

Contact Information

Headquarters:
1920 Yonge Street , Suite 200
Toronto, Ontario
M4S 3E2, Canada
Telephone: (416) 648-5555
Fax: (416) 572-7501
Email: Send a message
Website: Visit website